PL370495A1 - Sposób wytwarzania amorficznej postaci soli hemiwapniowej kwasu (3R,5R) 7-[3-fenylo-4-fenylokarbamoilo-2-(4-fluorofenylo)-5-izopropylopirol-1-ilo]-3,5-dihydroksyheptanowego (atorwastatyny) - Google Patents
Sposób wytwarzania amorficznej postaci soli hemiwapniowej kwasu (3R,5R) 7-[3-fenylo-4-fenylokarbamoilo-2-(4-fluorofenylo)-5-izopropylopirol-1-ilo]-3,5-dihydroksyheptanowego (atorwastatyny)Info
- Publication number
- PL370495A1 PL370495A1 PL03370495A PL37049503A PL370495A1 PL 370495 A1 PL370495 A1 PL 370495A1 PL 03370495 A PL03370495 A PL 03370495A PL 37049503 A PL37049503 A PL 37049503A PL 370495 A1 PL370495 A1 PL 370495A1
- Authority
- PL
- Poland
- Prior art keywords
- sub
- sup
- phenylcarbamoyl
- hemi
- pyrrol
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 4
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title 1
- 229960005370 atorvastatin Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 abstract 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 abstract 1
- 239000000920 calcium hydroxide Substances 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 150000001983 dialkylethers Chemical class 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 150000002596 lactones Chemical class 0.000 abstract 1
- -1 tert-butyl (6-{2-[3-phenyl-4-phenylcarbamoyl-2-(4-fluorophenyl)-5-isopropyl-pyrrol-1-yl]-ethyl}-2,2-dimethyl-[1,3]dioxane-4-yl) Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/04—Calcium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ20020413A CZ296967B6 (cs) | 2002-02-01 | 2002-02-01 | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL370495A1 true PL370495A1 (pl) | 2005-05-30 |
| PL209756B1 PL209756B1 (pl) | 2011-10-31 |
Family
ID=27674298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL370495A PL209756B1 (pl) | 2002-02-01 | 2003-01-30 | Sposób wytwarzania amorficznej postaci soli hemiwapniowej kwasu (3R,5R) 7-[3-fenylo-4-fenylokarbamoilo-2-(4-fluorofenylo)-5-izopropylopirol-1-ilo]-3,5-dihydroksyheptanowego (atorwastatyny) |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7208608B2 (pl) |
| EP (1) | EP1470106B1 (pl) |
| JP (1) | JP2005521685A (pl) |
| KR (1) | KR20040081172A (pl) |
| AT (1) | ATE480516T1 (pl) |
| AU (1) | AU2003213986A1 (pl) |
| CZ (1) | CZ296967B6 (pl) |
| DE (1) | DE60334068D1 (pl) |
| EA (1) | EA007432B1 (pl) |
| ES (1) | ES2347324T3 (pl) |
| HU (1) | HUP0402590A3 (pl) |
| PL (1) | PL209756B1 (pl) |
| PT (1) | PT1470106E (pl) |
| UA (1) | UA76826C2 (pl) |
| WO (1) | WO2003068739A1 (pl) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0409292A (pt) * | 2003-04-11 | 2006-04-11 | Lek Pharmaceuticals | processo para a preparação de sal de cálcio amorfo de atorvastatina |
| WO2005005384A1 (en) * | 2003-07-15 | 2005-01-20 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
| CN1942439B (zh) | 2004-03-17 | 2011-12-21 | 兰贝克赛实验室有限公司 | 无定形形式的阿托伐他汀钙的制备方法 |
| RU2412191C2 (ru) * | 2004-07-16 | 2011-02-20 | Лек Фармасьютиклз Д.Д. | Продукты окислительной деструкции кальций аторвастатина |
| WO2006011155A1 (en) * | 2004-07-26 | 2006-02-02 | Apollo International Limited | One pot process for amorphous atorvastain calcium |
| JP2008510798A (ja) * | 2004-08-27 | 2008-04-10 | バイオコン・リミテッド | 非晶質アトルバスタチンカルシウムのための方法 |
| JP2007515430A (ja) * | 2004-10-18 | 2007-06-14 | テバ ファーマシューティカル インダストリーズ リミティド | アルコール及びケトン、及び／又はエステルの混合物である有機溶媒に塩を溶解し、そして溶媒を除去することにより非晶質アトルバスタチンへミ−カルシウムの調製方法 |
| WO2006048893A2 (en) * | 2004-11-05 | 2006-05-11 | Morepen Laboratories Limited | A process for synthesis of large particle size statin compounds |
| CA2499047A1 (en) | 2005-03-01 | 2006-09-01 | Apotex Pharmachem Inc. | Process for producing atorvastatin hemicalcium |
| GB2424880A (en) * | 2005-04-06 | 2006-10-11 | Generics | Crystalline forms of atorvastatin sodium, processes for their preparation and their use in inhibiting HMG-CoA reductase |
| NZ566286A (en) | 2005-08-15 | 2010-06-25 | Arrow Int Ltd | Crystalline and amorphous sodium atorvastatin |
| AU2006281237A1 (en) | 2005-08-15 | 2007-02-22 | Arrow International Limited | Crystalline and amorphous sodium atorvastatin |
| ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
| HU227696B1 (en) * | 2006-04-13 | 2011-12-28 | Egyt Gyogyszervegyeszeti Gyar | Zinc salt of rosuvastatin, process for its preparation and pharmaceutical compositions containing it |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt |
| WO2009139730A1 (en) * | 2008-05-13 | 2009-11-19 | Ulkar Kimya San. Ve Tic. A.S. | Preparation of novel non-crystalline forms of atorvastatin calcium |
| KR101050722B1 (ko) * | 2008-12-02 | 2011-07-21 | 대웅바이오 주식회사 | 무정형 아토르바스타틴 칼슘염의 제조방법 |
| WO2010069593A1 (en) * | 2008-12-19 | 2010-06-24 | Krka, D. D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| EP2327682A1 (en) * | 2009-10-29 | 2011-06-01 | KRKA, D.D., Novo Mesto | Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates |
| US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| CZ201039A3 (cs) | 2010-01-19 | 2011-07-27 | Zentiva, K. S | Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme |
| WO2011131605A1 (en) * | 2010-04-19 | 2011-10-27 | Dsm Ip Assets B.V. | Production of atorvastatin low in ether impurities |
| CN108774164A (zh) * | 2018-05-29 | 2018-11-09 | 宣城美诺华药业有限公司 | 一种阿托伐他汀钙合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5248793A (en) | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| EP0848704B2 (en) * | 1995-07-17 | 2009-12-16 | Warner-Lambert Company LLC | Form iii crystalline ¬r-(r*,r*) -2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-¬(phenylamino)carbonyl -1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
| KR100431038B1 (ko) | 1995-07-17 | 2004-05-12 | 워너-램버트 캄파니 엘엘씨 | 결정질[ｒ-(ｒ*,ｒ*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1ｈ-피롤-1-헵탄산 헤미 칼슘염 (아토르바스타틴) |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| IN191236B (pl) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) * | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057228A1 (en) * | 2001-01-17 | 2002-07-25 | Biocon India Limited | Atorvastatin calcium |
| IN190564B (pl) * | 2001-04-11 | 2003-08-09 | Cadila Heathcare Ltd | |
| WO2003018547A2 (en) * | 2001-08-31 | 2003-03-06 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
-
2002
- 2002-02-01 CZ CZ20020413A patent/CZ296967B6/cs not_active IP Right Cessation
-
2003
- 2003-01-30 PT PT03709588T patent/PT1470106E/pt unknown
- 2003-01-30 PL PL370495A patent/PL209756B1/pl not_active IP Right Cessation
- 2003-01-30 UA UA20040907211A patent/UA76826C2/uk unknown
- 2003-01-30 AT AT03709588T patent/ATE480516T1/de not_active IP Right Cessation
- 2003-01-30 US US10/502,632 patent/US7208608B2/en not_active Expired - Lifetime
- 2003-01-30 JP JP2003567871A patent/JP2005521685A/ja active Pending
- 2003-01-30 WO PCT/CZ2003/000007 patent/WO2003068739A1/en not_active Ceased
- 2003-01-30 ES ES03709588T patent/ES2347324T3/es not_active Expired - Lifetime
- 2003-01-30 AU AU2003213986A patent/AU2003213986A1/en not_active Abandoned
- 2003-01-30 DE DE60334068T patent/DE60334068D1/de not_active Expired - Lifetime
- 2003-01-30 EP EP03709588A patent/EP1470106B1/en not_active Expired - Lifetime
- 2003-01-30 KR KR10-2004-7011960A patent/KR20040081172A/ko not_active Withdrawn
- 2003-01-30 HU HU0402590A patent/HUP0402590A3/hu unknown
- 2003-01-30 EA EA200400977A patent/EA007432B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1470106A1 (en) | 2004-10-27 |
| ATE480516T1 (de) | 2010-09-15 |
| HUP0402590A3 (en) | 2010-06-28 |
| WO2003068739A1 (en) | 2003-08-21 |
| EA007432B1 (ru) | 2006-10-27 |
| CZ296967B6 (cs) | 2006-08-16 |
| ES2347324T3 (es) | 2010-10-28 |
| UA76826C2 (uk) | 2006-09-15 |
| DE60334068D1 (de) | 2010-10-21 |
| US20050131055A1 (en) | 2005-06-16 |
| AU2003213986A1 (en) | 2003-09-04 |
| EP1470106B1 (en) | 2010-09-08 |
| HUP0402590A2 (hu) | 2005-03-29 |
| PL209756B1 (pl) | 2011-10-31 |
| US7208608B2 (en) | 2007-04-24 |
| KR20040081172A (ko) | 2004-09-20 |
| CZ2002413A3 (cs) | 2003-10-15 |
| EA200400977A1 (ru) | 2004-12-30 |
| PT1470106E (pt) | 2010-09-23 |
| JP2005521685A (ja) | 2005-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL370495A1 (pl) | Sposób wytwarzania amorficznej postaci soli hemiwapniowej kwasu (3R,5R) 7-[3-fenylo-4-fenylokarbamoilo-2-(4-fluorofenylo)-5-izopropylopirol-1-ilo]-3,5-dihydroksyheptanowego (atorwastatyny) | |
| CA2392025A1 (en) | Process for the preparation of amorphous atorvastatin | |
| ATE410413T1 (de) | Hydrolyse von är(r*,r*)ü-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol- heptansäureestern mit calciumhydroxid | |
| HU9403842D0 (en) | Compounds useful as sweeting a gents and process for their preparation | |
| AU2003299483A1 (en) | "crystalline aluminosilicate zeolitic composition: uzm-4m" | |
| EP1783113A3 (en) | Crystal form VII of atorvastatin hemi-calcium | |
| EP1783122A4 (en) | PROCESS FOR PREPARING AZULATE DERIVATIVES AND INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS | |
| CA2432064A1 (en) | Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide | |
| BG102186A (en) | Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin) | |
| BG102187A (en) | Crystall ine hemicalcium salt of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methyletyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h- pyrol-1-heptane acid (atorvastatin) | |
| IE51691B1 (en) | An antibacterial composition of thienamycin-type compound and a dipeptidase inhibitor | |
| EA200100955A1 (ru) | 4-ОКСО-4,7-ДИГИДРОТИЕНО [2,3-b]ПИРИДИН-5-КАРБОКСАМИДЫ В КАЧЕСТВЕ АНТИВИРУСНЫХ СРЕДСТВ | |
| AU4454597A (en) | Novel benzofuran-4-carboxamides | |
| WO2003018547A3 (en) | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) | |
| MXPA04007396A (es) | Proceso para la elaboracion de inhibidores de reductasa hmg-coa. | |
| JP2005521685A5 (pl) | ||
| AU2003293746A1 (en) | Crystalline cefdinir salts | |
| EP1429771A4 (en) | BICYCLIC COMPOUNDS AS AN INHIBITORS OF CHEMOKIN BINDING AT US28 | |
| IE881544L (en) | Phosphorous-containing hmg-coa reductase inhibitors and¹intermediates | |
| NO20062656L (no) | Fremgangsmate for fremstilling av statiner | |
| CA1245226A (en) | METHOD FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATE COMPOUNDS | |
| Coutrot et al. | Investigation of new potent KDO-8-phosphate synthetase inhibitors | |
| WO2007096903A3 (en) | New crystalline form of atorvastatin hemi-calcium | |
| DE69521012D1 (de) | Verfahren zur Herstellung von 1-(4,5-Dihydro)2-thiazolyl-3-Azetidinthiolderivaten | |
| WO2006066044A3 (en) | Processes for producing 4-aminoquinazolines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification | ||
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20130130 |